<DOC>
	<DOCNO>NCT00878449</DOCNO>
	<brief_summary>This Phase 1 Study Evaluating Safety ABT-263 Combination Etoposide/Cisplatin Subjects Small Cell Lung Cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Evaluating Safety ABT-263 Combination With Etoposide/Cisplatin Subjects With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Must great equal to18 year age ; For dose escalation subject must histologically and/or cytologically documented cancer etoposide/cisplatin determine appropriate therapy . For expanded safety cohort subject must histologically and/or cytologically document SCLC etoposide/cisplatin determine appropriate therapy ; Subject ECOG performance score less equal 1 ; Evaluable and/or measurable disease CT MRI per RECIST criterion ; Subjects brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 21 day prior 1st dose study drug ; Must adequate renal hepatic function , per local laboratory reference range Screening follow : ANC great equal 1500/mcL , Platelets great equal 150,000/mm^3 , Hemoglobin great equal 10.0 g/dL , Serum creatinine less equal 1.5 mg/dL calculate creatinine clearance great equal 50 mL/min ; Na great 130 mmol/L , Alkaline Phosphatase , AST ALTless equal 2.5 x ULN ; Bilirubin le equal 1.5 x ULN.Subjects liver mets may ALP , AST ALT less equal 5.0 x ULN , Subjects bone mets may Alkaline Phosphatase less equal 5.0 x ULN , Subjects Gilbert 's Syndrome may Bilirubin great 1.5 x ULN , Coagulation : aPTT , PT , less equal 1.2 x ULN ; Life expectancy least 30 day ; Female subject must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test ; Female subject surgically sterile postmenopausal ( least one year ) nonvasectomized male subject must practice least one method birth control . Subject exhibit evidence uncontrolled condition ( ) include , limited : active systemic infection , diagnosis fever neutropenia within 1 week 1st dose ; Subject underlying , predispose condition bleed currently exhibit sign bleed ; Subject currently receive require anticoagulation therapy ; Subject active immune thrombocytopenic purpura , autoimmune hemolytic anemia history refractory platelet transfusion ( within 1 year prior 1st dose study drug ) ; Subject active peptic ulcer disease hemorrhagic esophagitis/gastritis ; Subject significant history CV disease , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease ; Female subject pregnant breastfeeding ; Subject test positive HIV ; Subject history active malignancy within 3 year prior study entry , exception : adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin , previous malignancy confine surgically resect curative intent ; Subject receive anticancer therapy within 14 day prior 1st dose study drug ; Subject receive steroid therapy antineoplastic intent within 7 day prior 1st dose study drug ; Subject receive aspirin within 7 day prior 1st dose study drug ; Subject receive radioimmunotherapy within 6 month prior 1st dose study drug ; Subject receive antibody therapy biologics ( exception colony stimulate factor [ GCSF , GMCSF ] erythropoietin ) within 28 day prior 1st dose study drug ; Subject hypersensitivity platinumcontaining compound etoposide ; Subject consume grapefruit within 3 day prior 1st dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>